



DFE Pharma is a global leader in pharma- and nutraceutical excipient solutions. We develop, produce and supply high-quality functional excipients for use in the pharmaceutical, biopharmaceutical, and nutraceutical industries for respiratory, oral solid dose (OSD), ophthalmic and parenteral formulations. Our excipients are used in numerous medicinal and nutraceutical products, including COVID-19 vaccines and treatments.

Our excipients play an essential role as fillers, binders, disintegrants, and in stabilizing active ingredients for release predictably and effectively into the patients' system. With more than a century of experience and around 450 people worldwide, we are serving over 5,000 customers in 100+ countries worldwide.

## C2F: Bridging excipient excellence and formulation expertise

The new Center of Excellence "Closer to the Formulator" (C2F) by DFE Pharma helps pharmaceutical companies to shorten the time from a concept to a finished commercial product through expertise in all phases of pharmaceutical development.

The services offered by this new state-of-the-art facility, are mainly focused on Oral Solid Dosage (OSD) forms, comprising all types of pre-registration work including development, intermediate scale-up, and technology transfer.

The C2F offerings can provide pharmaceutical companies with multiple advantages as, for example, it aims to significantly lower the number of development cycles and aspires to reduce formulation costs, when launching a medicine.

Thanks to C2F capabilities, pharmaceutical companies, and formulators benefit from faster access to the market with high-quality products, robust formulations & processes, higher success rate and improved efficiency.



## From concept to commercial: End to end formulation development, lab and application support

Formulation development support: Through C2F, we share our formulation development advice on excipient choice, ratio and processing. This includes ingredients and steps, stability studies and specialized dosage forms such as orally disintegrating, effervescent, chewable, sublingual tablets, minitablets, etc. C2F capabilities also support efficiency projects such as conversion from wet granulation to direct compression.

Consultancy services: Including technical and analytical solutions across all lifecycle stages of the formulation development

We provide our expertise and support to meet any specific need within the formulation development or intermediate scale-up, resulting in higher levels of success as well as faster launch to market.

Regulatory services: Both Asia-dedicated and worldwide support in the registration and approval of new products, including user-friendly documentation and interpretation of regulations.

## State-of-the-art lab facilities in an exceptional location, the Genome Valley at Hyderabad

The cutting-edge 1200 sq meters laboratory facilities of the C2F center are equipped with the latest technology and staffed by highly experienced scientists. The equipment covers an instrumented tablet press, an automated capsule filling machine, a tablet coater, a blister packaging machine, stability chambers, and state-of-the-art analytical equipment.

The C2F center is based in Genome Valley, Hyderabad (India), the largest pharma and life sciences hub in Asia. It is a privileged location, where many major Indian and global (bio)pharmaceutical companies are present, as well as worldwide renowned research institutions and best-in-class supporting specialized infrastructure. This vibrant R&D cluster drives collaboration and innovation among some of the global key players in the pharmaceutical industry.

To know more about how C2F services can support your company, please reach us at c2f@dfepharma.com



